Drug Discovery

#Collaboration #Covid-19 #Drug discovery #Research

This week in drug discovery (30 August – 3 September) 

News round-up by DDW’s Megan Thomas for 30 August – 3 September  DDW’s Megan Thomas has rounded up five stories in which studies, collaborations and trials pave the way towards treatments for a number of potentially fatal conditions.   1. NIH studies Covid-19 vaccine dose for… Read More

#News

#Biopharmaceuticals #Drug development #Webinar

Webinar: learn how to accelerate biosimilar development

Using an automated CE-SDS platform in efficient biosimilar comparability studies is a free-to-attend webinar which will be hosted by DDW and supported by Bio-Techne on 29 September at 4PM BST. Watch on Demand here. Join Dr Richard L Easton, Technical Director of Structural Analysis at BioPharmSpec as he discusses… Read More

#News #Trending News

#Drug development #Oncology #Therapeutics

Avacta appoints Chief Scientific Officer of therapeutics division

Avacta has appointed Dr Fiona McLaughlin as Chief Scientific Officer of its therapeutics division, effective immediately. Dr McLaughlin is an experienced oncology drug developer, bringing over 25 years’ experience in research and translational drug development in the pharmaceutical and biotech sectors, having led teams from early research through to clinical… Read More

#Business & Investment #News

#Drug discovery #Drug repurposing

Viagra can strongly suppress abnormal heart rhythms, finds study 

Scientists from the University of Manchester have found that the drug Viagra, used to treat sexual impotence, can strongly suppress abnormal heart rhythms known as arrythmias in sheep.  The British Heart Foundation funded study, published in Circulation Research, could have important implications on the management of the… Read More

#News

#Cardiovascular disease #Collaboration #Drug discovery

Novartis collaboration has potential to improve heart health in UK 

Novartis and NHS England are to pioneer a population health management approach to address elevated LDL-C in patients with Atherosclerotic Cardiovascular Disease (ASCVD) across England.  The collaboration received positive final recommendation from the National Institute for Health and Care Excellence (NICE) for use of inclisiran in primary care for the treatment of adult patients within… Read More

#Business & Investment #News

#Biopharmaceuticals #Clinical trials #Drug development #Drug discovery

Building a pipeline of clinically-differentiated cancer therapies 

As previously reported by DDW, Avacta Group has dosed the first patient in its Phase I multicentre trial evaluating AVA6000, a novel pro-drug of Doxorubicin and the company’s first therapeutic based on its pre|CISION technology. Megan Thomas speaks Dr Alastair Smith, Chief Executive Officer of Avacta Group, about this development.  … Read More

#Editor's Choice #Exclusive Content #News #Opinion

#Covid-19 #Drug development #Drug discovery #Podcast #Therapeutics

How Bamlanivimab reached clinic in eight months – podcast 

The latest DDW Sponsored Sitting Down With podcast features Bryan Jones, Senior Research Fellow, BioTechnology Discovery Research, Eli Lilly and Co and Dan Bedinger, Application Science Team Lead, Carterra. Bamlanivimab was the first neutralising monoclonal antibody to receive emergency use authorisation from the FDA as a treatment for mild… Read More

#Covid-19 #News

#Biomedicine #Cell and gene therapy #Drug development

BioIVT launches human AB serum for cell and gene therapy development 

BioIVT’s human AB serum product line is designed to supplement cell culture media and facilitate cell and gene therapy development.  Human AB serum contains many compounds that are vital for cell growth, including growth factors, vitamins, nutrients, trace elements and transport factors. As a result, human… Read More

#News

#Cancer research #Clinical trials #Drug development #Drug discovery #Institute of Cancer Research

New cancer drug to enter first clinical trial targeting HSF1 pathway 

The Institute of Cancer Research (ICR), London has discovered an investigational drug called NXP800, which cancer patients are set to receive for the first time. It was discovered in a Phase I clinical trial sponsored by an oncology-focused biopharmaceutical company, Nuvectis Pharma.  The investigational oral drug inhibits the so-called… Read More

#Cancer Research #Trending News

#Biopharmaceutical #Clinical trials #Drug delivery #Drug development

First patient dosed in izokibep trial for patients with active AS

Inmagene Biopharmaceuticals and Affibody have dosed the first patient in the global ASPIRE Phase II trial evaluating izokibep (IMG-020 or ABY-035) for the treatment of ankylosing spondylitis (AS).  “Dosing the first patient in the global Phase II AS trial is an important milestone for the izokibep programme,” said Dr. Jean-Louis Saillot, Inmagene’s Chief… Read More

#News

#Assays #Cell and gene therapy #Drug development #Immunology

Collaboration agreement for ImmunoBiopsy platform 

Orgenesis has entered into a collaboration agreement with Savicell Diagnostics to deploy Savicell’s patented ImmunoBiopsy immunometabolism platform. The aim is to develop and validate diagnostic kits for enhanced quality control (QC) and monitoring purposes to be used by Orgenesis in manufacturing and processing of its cell and gene therapies. New assays will be developed to enhance the potency… Read More

#Business & Investment #News

#Clinical trials #Diabetes #Drug development #Eye

Scientists prepare to trial new nano-drug for eye diseases 

Professor Di Yu of the UQ Diamantina Institute collaborated with scientists from the Chinese Academy of Sciences and Beijing Chaoyang Hospital to address age-related macular degeneration and retinal neovascularisation linked to diabetes, which affect approximately 450 million people worldwide. This has been published in Nature Biomedical Engineering.  Currently, treatments… Read More

#News

#Biologics #Drug discovery #Drug therapy #Events #Immunotherapy

Two-day biologics drug discovery course open for registration 

Join Terrence Kenakin as he presents a two-day Applied course on September 21 and September 22 at 10AM CDT.   This two-day course will introduce the topic of biologics as a drug therapy in addition to recombinant replacement protein biologics, peptide signalling, immunotherapy, antibodies features, and nucleotide-based… Read More

#News

#Antibodies #Biotherapeutics #Collaboration #Drug discovery

Collaboration to support preclinical drug discovery research 

Fusion Antibodies has entered into a commercial collaboration with Eurofins to provide laboratories worldwide with high-quality, cost-effective and efficient services that work with one another to support biotherapeutic discovery.   Under the agreement, Fusion Antibodies will provide comprehensive pre-clinical antibody development services from discovery, engineering, and critical reagent supply to… Read More

#Business & Investment #News

#AI #Drug development #Immuno-oncology #Machine learning #Oncology

Bristol Myers Squibb develops Exscientia’s drug candidate 

Exscientia has announced that Bristol Myers Squibb has elected to in-license its immune-modulating drug candidate. Exscientia has two active collaborations with Bristol Myers Squibb, which together focus on multiple therapeutic areas, including oncology and immunology. A significant expansion of the relationship was announced earlier this year.  The in-licensed candidate targets… Read More

#Cancer Research #News

#Cell therapy #Diabetes #Drug development #Immunology #Life sciences

Dundee professor joins GSK’s Immunology Network 

Professor of Cellular Immunology at the University of Dundee’s School of Life Sciences, Doreen Cantrell, has been selected to join GSK’s Immunology Network, a programme designed to embed academic scientists in GSK laboratories with the goal to broaden scientific insight and drive major breakthroughs in applied immunology. … Read More

#News